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Abstract
1. Catechol-O-methyltransferase (COMT) is involved in the O-methylation of L-DOPA, dopa-
mine, and other catechols. The enzyme is expressed in two isoforms: soluble (S-COMT),
which resides in the cytoplasm, and membrane-bound (MB-COMT), which is anchored to
intracellular membranes.
2. To obtain specific information on the functions of COMT isoforms, we studied how a
complete MB-COMT deficiency affects the total COMT activity in the body, peripheral
L-DOPA levels, and metabolism after L-DOPA (10mg kg1) plus carbidopa (30mg kg1)
administration by gastric tube in wild-type (WT) and MB-COMT-deficient mice. L-DOPA and
3-O-methyl-L-DOPA (3-OMD) levels were assayed in plasma, duodenum, and liver.
3. We showed that the selective lack of MB-COMT did not alter the total COMT activity, COMT
enzyme kinetics, L-DOPA levels, or the total O-methylation of L-DOPA but delayed
production of 3-OMD in plasma and peripheral tissues.
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Introduction
Catechol-O-methyltransferase (COMT) catalyzes the conver-
sion of catecholamines and other catechols, e.g. L-DOPA and
catechol estrogens, into their O-methylated metabolites using
S-adenosyl-L-methionine as the methyl donor (Guldberg &
Marsden, 1975; Ma¨nnisto¨ & Kaakkola, 1999). The COMT
gene (COMT) codes for two isoforms of the COMT enzyme
protein, soluble (S-COMT), and membrane-bound (MB-
COMT) (Lundstro¨m et al., 1991; Salminen et al., 1990).
The latter protein is slightly larger because it incorporates 50
additional hydrophobic amino acids that form the membrane
anchor (Lundstro¨m et al., 1991; Bertocci et al., 1991). COMT
contains six exons, the first two of which are non-coding. In
exon 3, there are two AUG start codons for two promoters that
control the expression of the two COMT transcripts
(Tenhunen et al., 1994). The distal P2 promoter regulates
the synthesis of a 1.5-kb transcript in humans. Based on the
leaky scanning mechanism of translation initiation, this longer
transcript can code for both S-COMT and MB-COMT
proteins (Tenhunen & Ulmanen, 1993; Tenhunen et al.,
1993, 1994). The P1 promoter almost completely overlaps
exon 3 and falls between the S-COMT and MB-COMT ATG
start codons, partially overlapping the MB-COMT coding
sequence. Therefore, the shorter mRNA transcript (1.3 kb in
humans) regulated by P1 only codes for the S-COMT protein.
S-COMT and MB-COMT share the same enzymatic
mechanism, but their kinetic parameters for catecholamine
neurotransmitters are different. S-COMT shows high Km
values but also high Vmax values, suggesting that S-COMT is
the predominant isoenzyme under conditions where substrate
concentrations are high, such as during detoxification of
exogenous catechol compounds in the liver and gut wall
(Guldberg & Marsden, 1975; Ma¨nnisto¨ & Kaakkola, 1999;
Roth, 1992). MB-COMT, on the contrary, has low Vmax
values as well as a higher affinity to catechol substrates than
S-COMT, implying a role in catecholamine neurotransmitter
metabolism under low, evidently physiological concentrations
(Bai et al., 2007; Lotta et al., 1995; Masuda et al., 2006; Roth,
1992). Nevertheless, differences in these kinetic parameters
are not universal for all substrates. In the case of many
catechol compounds, such as L-DOPA, 3,4-dihydroxybenzoid
acid (DHBAc) and catecholestrogens, the affinity and rate of
enzymatic reaction are similar for both isoenzymes (Lotta
et al., 1995; Reid et al., 1986).
COMT is expressed widely in tissues throughout the body.
The highest levels of expression are found in the liver and
kidneys (Guldberg & Marsden, 1975; Ma¨nnisto¨ & Kaakkola,
1999; Myo¨ha¨nen & Ma¨nnisto¨, 2010). Distribution of COMT
activity does not fully parallel COMT protein levels,
suggesting that the activity is regulated at the tissue level.
In addition, the S-COMT/MB-COMT ratio varies between
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tissues, which likely affects the relation between combined
COMT expression levels and enzyme activity (Myo¨ha¨nen &
Ma¨nnisto¨, 2010). Generally, the importance of MB-COMT-
mediated O-methylation is higher in the brain than in the
periphery, and S-COMT expression and activity levels are
higher in peripheral tissues than in the brain (Ma¨nnisto¨ &
Kaakkola, 1999; Myo¨ha¨nen et al., 2010). Since estrogens
down-regulate the expression of both COMT isoforms,
COMT activity is generally lower in females than males
although not in all tissues (Schendzielorz et al., 2011; Xie
et al., 1999). Significance of the COMT gene to sex
differences in brain function and predisposition to psychiatric
disorders has remained unsolved (Tunbridge & Harrison,
2011).
The dopamine precursor L-DOPA, combined with an
aromatic acid decarboxylase (AADC, DDC, dopa decarb-
oxylase) inhibitor like carbidopa, is the most important
component of treatment for Parkinson’s disease (PD). COMT
inhibitors, such as entacapone and tolcapone, are used in PD
to improve further the bioavailability of L-DOPA and prolong
its action (Ma¨nnisto¨ & Kaakkola, 1999).
We have developed a novel genetically engineered mouse
strain that selectively lacks MB-COMT (Tammima¨ki et al.,
2016). These mice had a distinct phenotype with increased
aggressiveness, reduced prepulse inhibition, and prolonged
immobility time in tail suspension test in male mice and
sensitization to pain and worsened short-term memory in both
sexes. Earlier, we found in S-COMT-deficient mice that the
total COMT activity was decreased by about 30% in all
tissues studied (Ka¨enma¨ki et al., 2009). However, after
L-DOPA/cardidopa administration, the levels of L-DOPA
either in plasma or peripheral tissues were only slightly
increased, although the levels of the O-methylated metabolite
of L-DOPA, 3-OMD, were significantly decreased. Based on
that, we hypothesized that overall COMT activity would be
decreased in MB-COMT-deficient mice and that the periph-
eral metabolism of L-DOPA would be hampered as well.
In the present study, L-DOPA kinetics after oral adminis-
tration of L-DOPA with carbidopa was explored. We
measured L-DOPA and 3-OMD levels in plasma and periph-
eral tissues of the WT and MB-COMT-deficient mice. These
studies provide new information on the role of COMT
isoforms in L-DOPA metabolism in mice.
Materials and methods
Materials
L-DOPA (levodopa), 3-OMD, and 3,4-dihydroxybenzoid acid
(DHBAc) were purchased from Sigma Chemical Co. (St.
Louis, MO), and carbidopa was obtained from Orion Pharma
(Espoo, Finland). Carboxymethyl cellulose and EDTA were
purchased from Fluka Chemie (Steinheim, The Netherlands).
Animals
MB-COMT knock-in mutant mice were generated as
described elsewhere (Tammima¨ki et al., 2016). Briefly, a
knock-in approach was used that allowed site-directed muta-
genesis on the whole animal level. Two-point mutations
were introduced in exon 2 of the Comt gene (ATGCTG
–>GAGCTC) altering just one amino acid, methionine, to
glutamic acid. Consequently, the function of the P2 promoter
is disabled and only the P1-regulated S-COMT transcription
remains.
MB-COMT-deficient male and female mice as well as
their WT littermates were used for the animal experiments.
The mice were bred in a SPF barrier unit at the Laboratory
Animal Centre of University of Helsinki, Finland. They were
weaned, sexed, and earmarked at the age of 3 weeks. After
weaning, they were group housed in clear polycarbonate
individually ventilated filter-top cages with aspen chip
bedding and nesting material under 12:12 light cycle at an
ambient temperature of 22 C with drinking water and mouse
chow available ad libitum. The mice were kept in the home
cages with their same-sex littermates until sacrificed. Mice (in
total 146 mice) of the sixth to seventh generations of
heterozygous mating pairs were used for the experiments;
C57BL/6JHsd mice were regularly included in the breeding to
maintain the strain on that particular background.
Experimentally naı¨ve animals entered the experiments when
they were two to three months old and weighed 20–30 g. The
phase of the estrus cycle was not determined. In all
experiments, MB-COMT-deficient male and female groups
were compared with respective WT control groups. In the end
of experiments, the animals were sacrificed by cervical
dislocation.
Animal experiments were conducted according the 3R
principles of the EU directive 2010/63/EU governing the care
and use of experimental animals, and following local laws and
regulations [Finnish Act on the Protection of Animals Used
for Scientific or Educational Purposes (497/2013),
Government Decree on the Protection of Animals Used for
Scientific or Educational Purposes (564/2013)]. The protocols
were authorized by the national Animal Experiment Board of
Finland.
Genotyping of MB-COMT-deficient knock-in mice
Genotype was determined from tissue samples obtained
during earmarking of the mice. Genomic DNA was extracted
from the ear biopsies as described by Laird et al. (1991). PCR
mix consisted Comt3HAUF2 (oligo No: 40612F3A03 1/4,
sequence: 50-GAAGTGGGTATGGCAGCGCTTATA-30) and
Comt5HADR2 (oligo no. 40612F3B03 2/4 sequence:
50-AACACACATTCCTCTC-ATGCTCCT-30) primers from
Oligomer (Helsinki, Finland) and Fail safe system premix
B. The amplified fragments were visualized by SyBr Green
(Qiagen, Venlo, The Netherlands) staining under ultraviolet
light after electrophoresis in a 1.7% agarose gel.
COMT activity assay
Livers for total COMT activity assay were collected from
MB-COMT-deficient and WT mice of both sexes. The tissues
were frozen on dry ice and stored at 80 C before analysis.
Detailed method of the COMT activity assay is given
elsewhere (Ka¨enma¨ki et al., 2009). Activity data are given
as picomoles of vanillic acid (and isovanillic acid for meta/
para calculation) formed per minute per milligram of tissue.
Liver COMT activities were measured with graded concen-
trations of DHBAc (1, 10, and 100 mM) and enzyme kinetics
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(Km and Vmax) were calculated with GraphPad Prism 5.0. (San
Diego, CA).
Western blotting
For Western immunoblotting (WB), the tissue samples (liver
and duodenum) were collected from at least two male and two
female mice and rinsed in physiological saline solution.
Immediately after dissection, the tissues were placed in ice-
cold centrifuge tubes on dry ice to minimize decomposition.
All the tissue samples were frozen and stored in –80 C until
analyzed. Tissues were lysed in 10 volumes of RIPA lysis
buffer (20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10%
glycerol, 1% NP-40, 2 mM EDTA) containing protease and
phosphatase inhibitors, homogenized manually, incubated for
20 min on ice and centrifuged (18 000  g for 15 min at 4 C).
The supernatants were resolved by electrophoresis on a
4–20% precast gel (Mini Protean TGX Gel, Biorad, Hercules,
CA). Proteins were transferred onto Trans-Blot Turbo
Nitrocellulose filter and transferred using the Trans-Blot
Turbo Transfer system (Biorad, Hercules, CA). The mem-
branes were blocked with 0.1% (w/w) Tween-20/TBS
containing 5% (w/w) non-fat-dried milk at room temperature
for 1 h. After blocking, the membranes were incubated
overnight with mouse anti-COMT antibody (1:8000, BD
Biosciences, Franklin Lakes, NJ) and mouse anti b-actin
antibody (1:10 000, clone AC-74, purified immunoglobulins,
107K4791, Sigma-Aldrich Inc., MO) followed by incubation
with goat anti-mouse secondary antibody, HRP conjugated
(1:2000, Thermo Fisher Scientific, Waltham, MA) for 1 h at
room temperature. The membranes were incubated with ECL
detection reagent (Thermo Fisher Pierce, Rockford, IL) for
5 min to visualize proteins, and then visualized using C-Digit
blot scanner (Li-COR, Lincoln, NE). Blots were analyzed
using ImageJ freeware (NIH, Bethesda, MD).
Pharmacokinetics of L-DOPA
The mice were given L-DOPA (10 mg kg1) and carbidopa,
30 mg kg1) suspended in 0.25% carboxymethyl cellulose gel
(volume 5 ml kg1) with a silicon-tipped stainless steel gastric
tube. The drug doses were chosen to match the ones used in
our previous L-DOPA studies (Huotari et al., 2002; Ka¨enma¨ki
et al., 2009). From each mouse, one baseline blood sample
and two blood samples after L-DOPA administration were
collected in Microvette capillary blood collection tubes
containing potassium EDTA (Sarstedt, Nu¨mbrecht,
Germany) at time points 30, 60, and 120 min. The first two
samples (100ml) were taken from the saphenous vein (https://
www.nc3rs.org.uk/mouse-saphenous-vein-non-surgical) and
the third, terminal sample (approximately 300 ml of the
whole trunk blood) by decapitation of the cervically
dislocated animals. The blood samples were centrifuged at
4900  g at 4 C for 10 min. We aimed to collect six
independent samples of each genotype at every time point was
measured. After the terminal blood sample (at 60 or 120 min)
was collected by decapitation, pieces of the liver and
duodenum were dissected and frozen on dry ice. Control
tissues (shown as time point 0 in results) were collected from
drug-naı¨ve mice. Plasma and tissues were stored at 80 C
until assays.
Plasma (Ka¨enma¨ki et al., 2009) and tissue (Airavaara et al.,
2006; Huotari et al., 2002) samples were prepared as
previously described and L-DOPA and 3-OMD were quanti-
fied from the filtrates using HPLC with electrochemical
detection as described in (Ka¨enma¨ki et al., 2009). The values
are presented as nanograms per mg of wet tissue weight or
nanograms per ml of plasma. The number of animals per
group in these analyses was 4–7. In our experience, this
number is large enough to show potential significant differ-
ences between groups. There were seven animals in male WT
group at 0 min, six animals in male MB-COMT-deficient
mice a 0 min, female WT mice at 120 min, female MB-
COMT-deficient mice at 60 min and female MB-COMT-
deficient mice at 120 min groups and four animals in female
WT 0 min group. Rest of the groups had five animals. Four
tissue samples were excluded due to failed sample preparation
or analysis. Thus, in these groups, there are fewer replications
than in others (male WT mice at 60 min, female MB-COMT-
deficient mice at 30 and 60 min).
Statistics
SPSS 22 statistic software (SPSS Inc., Chicago, IL) was used
for all calculations. The results are shown as mean ± standard
error of mean (SEM). AUC values were calculated employing
the trapezoidal rule (calculated of time points between 0 and
120 min).
Two-way ANOVA for repeated measures with sex and
genotype as independent variables was used to test the
L-DOPA kinetic data and COMT enzyme activity. If the
initial two-way ANOVA showed a significant sex effect,
the data were further analyzed with one-way ANOVA for
repeated measures. Differences in L-DOPA/3-OMD ratios at
each time point were analyzed by two-way ANOVA and meta/
para ratios with one-way ANOVA followed by Newman–
Keuls test.
Results
COMT proteins in the liver and duodenum
Representative Western blots from duodenum and liver of
male and female WT and MB-COMT-deficient mice
(Figure 1) show that the latter express S-COMT protein,
while no MB-COMT protein is present. The amount of MB-
COMT is about one-tenth of S-COMT. We did not see any
Figure 1. Western blot analysis of the liver and duodenum showing a
complete lack of MB-COMT protein in the mutated mice. WT: wild-
type, –/–: MB-COMT-deficient mice.
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upregulation of S-COMT as a reaction to the lacking MB-
COMT.
Total COMT activity in the liver
As expected, increased total COMT activity in the liver
(Figure 2) was observed with increasing concentrations of the
substrate without any significant difference between the
values in the WT and MB-COMT-deficient mice. There
were no significant differences in the kinetic values between
genotypes and sexes calculated from the present substrate
concentrations (1, 10, and 100 mM) and those measured
earlier at 3, 30, and 300 mM (Tammima¨ki et al., 2016): Vmax:
in males, 481 ± 65 versus 385 ± 57 min1 in WT and MB-
COMT-deficient mice, and in females, 381 ± 113 versus
536 ± 110 min1, respectively; Km: in males, 115 ± 56 versus
89 ± 27 mM, and in females, 180 ± 79 versus 277 ± 75 mM, in
WT and MB-COMT-deficient mice, respectively.
However, there was a sex difference in liver COMT
activity across different substrate concentrations [two-way
ANOVA for repeated measures: F2, 40 = 8.645, p50.01].
Meta/para ratios were always less than 15, typical to S-COMT
activity, at all substrate levels. In all material, meta/para ratios
of the males were 12.0 ± 1.4 (WT) and 11.6 ± 1.7 (MB-
COMT deficient) and in females, 6.7 ± 0.4 and 6.5 ± 0.4,
respectively. Female values were significantly lower than
male values [one-way ANOVA: F3,50 = 6.81, p50.01].
Pharmacokinetics of L-DOPA
L-DOPA and 3-OMD in plasma
Figure 3 shows the concentrations of L-DOPA and its 3-OMD
in the plasma of the MB-COMT-deficient mice and their WT
littermates of both sexes. Neither the sex nor the genotype
affected concentrations of L-DOPA in plasma. Although there
was neither a genotype- nor sex-dependent effect on 3-OMD
levels, the interaction between the two was significant [two-
way ANOVA for repeated measures, sex genotype inter-
action: F1, 17 = 5.338, p50.05]. This means that genotype
had a different effect on 3-OMD levels in males than in
females. In practice, male mice showed no genotype effect
whereas in females the 3-OMD levels tended to be lower in
MB-COMT deficient than in WT mice. Furthermore, the
kinetics of the 3-OMD was altered in the MB-COMT-
deficient mice, as the levels of 3-OMD did rise more slowly in
the mutated mice as compared with the WT animals [two-way
ANOVA for repeated measures, time genotype interaction
F4, 68 = 6.965, p50.001].
L-DOPA/3-OMD ratios at 30 min confirmed that O-
methylation of L-DOPA was significantly delayed in both
male (WT, 4.3 ± 1.6 versus MB-COMT deficient, 11.8 ± 1.1)
and female (5.3 ± 0.7 versus 14.8 ± 1.1) MB-COMT-deficient
mice [two-way ANOVA: genotype effect F1, 16 = 19.42,
p50.01]. However, there was a significant overshooting of
O-methylation at 120 min in MB-COMT-deficient mice
(males: 3.1 ± 0.5 versus 0.5 ± 0.2; females: 4.0 ± 1.4 versus
0.5 ± 0.08, for WT and MB-COMT deficient, respectively)
[two-way ANOVA: genotype effect F1,18 = 6.65, p50.05].
L-DOPA and 3-OMD in tissues
Figure 4 shows that neither the gender nor the genotype
significantly affected the L-DOPA levels in hepatic and
duodenal tissues. In addition, neither sex nor genotype
affected hepatic and duodenal concentrations of 3-OMD.
However, in both tissues, genotype affected the 3-OMD levels
in male mice measured over time [two-way ANOVA for
repeated measures, liver: time genotype interaction F2, 30
= 6.990, p50.01; duodenum: time genotype interaction F2,
30 = 5.617, p50.01]. Like 3-OMD levels in plasma, also 3-
OMD tissue levels appeared to increase more slowly in MB-
COMT-deficient mice as compared with their WT littermates
(excluding duodenal tissue in females).
Discussion
In this study, we explored the effect of complete MB-COMT
deficiency on hepatic COMT activity and L-DOPA kinetics
and metabolism in mouse. We showed that the lack of MB-
COMT affected neither the total COMT activity in the liver
nor L-DOPA levels in but shifted the 3-OMD time–concen-
tration curve to the right in plasma and peripheral tissues.
In our previous studies in S-COMT-deficient mice, we
found a non-significant 20–30% increase of L-DOPA levels in
the plasma, liver and duodenum (Ka¨enma¨ki et al., 2009),
while in the COMT knock-out mice, L-DOPA levels were
approximately doubled as compared with the WT mice
(Ka¨enma¨ki et al., 2009). In the present study, we did not
observe a significant overall effect of MB-COMT genotype
on 3-OMD levels in the plasma and peripheral tissues
(Figures 3 and 4). Instead, in the MB-COMT-deficient
mice, we observed a significant delay in plasma and
peripheral tissue 3-OMD levels as compared with WT
animals. This was reflected in the significantly reduced
L-DOPA/3-OMD ratios at 30 min in the MB-COMT-deficient
mice of both sexes. At 120 min, there was an overshoot of the
ratio balancing the total L-DOPA O-methylation to the level
of the WT mice. In the previous study, we showed 30–40%
lower 3-OMD levels in plasma, liver, and duodenum in
S-COMT-deficient animals than in their WT littermates
Figure 2. Total COMT activity in the liver (mean ± SEM, n= 4–5/
group) measured at three substrate (DHBAc) concentrations (1, 10, and
100mM). There was a significant sex effect females having generally
lower COMT activity than males. However, the lack of MB-COMT did
not alter the total COMT activity.
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(Ka¨enma¨ki et al., 2009). Altogether, these results suggest that
S-COMT can effectively compensate functionally for the
deficit caused by the lack of the MB-COMT isoform. The
delayed initial metabolism of L-DOPA was an exception,
stressing an unexpected importance of MB-COMT in the
peripheral metabolism of L-DOPA where S-COMT was not
fully able to compensate for the lack of MB-COMT.
Enzyme kinetic properties of pure recombinant human
COMT isoforms for L-DOPA, dopamine and noradrenaline
have shown that compared with S-COMT, the Vmax (capacity)
of MB-COMT for L-DOPA, DHBAc (the substrate of activity
assay), dopamine, and noradrenaline is about one-half,
whereas the affinity (Km) for L-DOPA is only two-fold (for
DHBAc even less) but more than 10-fold for both catechol-
amines. The amount of MB-COMT protein was about 10% of
that of S-COMT in the duodenum. Also in our earlier study,
the amount of MB-COMT in the mouse duodenum was
considerably smaller than that of S-COMT (Myo¨ha¨nen et al.,
2010). The relatively small affinity difference between MB-
COMT and S-COMT for L-DOPA probably means that
MB-COMT is participating to a minor extent in L-DOPA
O-methylation in the upper gastrointestinal tract in the WT
mice and, therefore, a lack of MB-COMT may contribute to
the initial delay of L-DOPA O-methylation.
Unaltered total COMT activity in the mice lacking MB-
COMT could be explained by significant differences of
enzyme kinetic properties of the two COMT isoforms for
catecholamines (see Introduction and the preceding para-
graph) as we have thoroughly discussed before (Tammima¨ki
et al., 2016). Km value of MB-COMT for catecholamines is
less than one-tenth (or even smaller in some studies, Roth,
1992) of the corresponding value of S-COMT. In addition, the
meta/para ratio suggests dominance of O-methylation by S-
COMT even in WT mice (less than 15) and this ratio was not
altered by a complete lack of MB-COMT. Considering the
dominance of behavioral effects of MB-COMT deficiency in
males (Tammima¨ki et al., 2016), it is notable that meta/para
ratios were significantly higher in males than females,
suggesting an important role for MB-COMT, particularly in
males. There is no doubt that S-COMT is the dominating
Figure 3. l-DOPA and 3-OMD in plasma. Concentrations of L-DOPA and 3-OMD in the plasma of male and female MB-COMT-deficient animals and
their wild-type littermates as well as AUC0–120 min values calculated based on time–concentration curves. The mice were treated with L-DOPA (10 mg/
kg) and the dopa decarboxylase inhibitor carbidopa (30 mg/kg) by gastric tube and blood samples were taken at 30, 60, 90, and 120 min after drug
administration. Control blood was drawn before drug administration. From each mouse, three blood samples were taken. The time points of blood
sampling were randomized within each genotype and sex group. WT: wild-type, MB-COMT / : MB-COMT-deficient mice. One-way ANOVA for
repeated measures indicated a significant time effect for both sexes in L-DOPA and 3-OMD data analyses. However, genotype time interaction proved
to be significant only for the male 3-OMD levels. One-way ANOVA F-values are presented in the figure. Data are given as mean ± SEM, n= 5–7 per
time point.
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Figure 4. L-DOPA and 3-OMD in peripheral tissues. Concentrations of L-DOPA and 3-OMD in hepatic and duodenal tissue from MB-COMT-deficient
mice and their wild-type (WT) littermates as well as AUC0-120 min values based on time–concentration curves. The mice were treated with L-DOPA
(10 mg/kg) and the dopa decarboxylase inhibitor carbidopa (30 mg/kg) by gastric tube. Mice were sacrificed 60 or 120 min after drug administration.
Control tissues were collected from drug-naı¨ve mice. WT: wild-type; MB-COMT /= MB-COMT-deficient mice. One-way ANOVA for repeated
measures indicated a significant time effect for L-DOPA in females in the liver and in both sexes in the duodenum and 3-OMD in both sexes and tissues.
However, genotype time interaction proved to be significant only for 3-OMD in males. One-way ANOVA F-values are presented in the figure. Data
are given as mean ± SEM, n= 5–7 per time point.
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enzyme of overall COMT activity in the body. It is interesting
to note that in the S-COMT-deficient mice (Ka¨enma¨ki et al.,
2009), MB-COMT was able to maintain about 70% of the
total COMT activity, suggesting that under extreme condi-
tions MB-COMT can compensate for missing S-COMT
protein. We do not report brain tissue levels of L-dopa, 3-
OMD, or dopamine after L-DOPA plus carbidopa adminis-
tration in this article, but after a similar treatment, we earlier
found profound alterations in the extracellular dopamine
levels in microdialysis studies (Tammima¨ki et al., 2016).
Notably, dopamine levels were increased in the striatum but,
instead, decreased in the prefrontal cortex in the MB-COMT-
deficient mice compared with the WT mice. MB-COMT
certainly has a function under normal conditions as well, and
the behavioral phenotype of MB-COMT-deficient mice gives
hints of its functional role in some brain areas (Tammima¨ki
et al., 2016). However, in peripheral L-DOPA metabolism, the
effect of MB-COMT can be considered marginal, and our
finding does not have any eminent clinical significance.
Present COMT inhibitors inhibit both isoforms of COMT
(Ma¨nnisto¨ & Kaakkola, 1999) and, therefore, the peripheral
distribution profile remains insignificant.
In conclusion, our initial hypothesis did not turn out to be
true. In the MB-COMT-deficient mice, S-COMT is generally
capable of maintaining a normal level of COMT function and
enzyme kinetics. L-DOPA levels and 3-OMD formation after
L-DOPA plus carbidopa administration do not change signifi-
cantly in the absence of MB-COMT, but the 3-OMD
concentration–time curve shifts to the right in plasma and
peripheral tissues, suggesting a temporarily delayed L-DOPA
O-methylation.
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